pulmoПульмонологияPULMONOLOGIYA0869-01892541-9617Scientific and Practical Journal “PULMONOLOGIYA” LLC10.18093/0869-0189-2024-34-4-544-551pulmo-4389Research ArticleОБЗОРЫREVIEWРак легкого и беременностьLung cancer and pregnancyhttps://orcid.org/0000-0002-8194-2811ЧернышоваА. Л.ChernyshovaA. L.

Чернышова Алена Леонидовна – д. м. н., профессор Российской академии наук, директор Института онкологии и нейрохирургии ФГБУ «НМИЦ им. Ак. Е.Н. Мешалкина» МЗ РФ; ведущий научный сотрудник отделения гинекологии НИИ онкологии – филиала ФГБНУ «Томский НИМЦ РАН»; профессор кафедры онкологии ФГБОУ ВО «НГМУ» МЗ РФ.

630055, Новосибирск, ул. Речкуновская, 15; 634028, Томск, ул. Савиных, 12 / 1; 630091, Новосибирск, Красный проспект, 52

Тел.: (913) 824-60-72

Author ID 55220758100; Reseacher ID (WOS) C-8608-2012

Alyona L. Chernyshova - Doctor of Medicine, Professor, Russian Academy of Sciences; Director of the Institute of Oncology and Neurosurgery, Federal State Budgetary Institution “National Medical Research Center named after Academician E.N. Meshalkin”, Ministry of Health of the Russian Federation; Leading Researcher, Department of Gynecology, Cancer Research Institute Cancer Research Institute is a Subdivision of the Federal State Budgetary Scientific Institution “Tomsk National Research Medical Center of the Russian Academy of Sciences”; Professor, Department of Oncology, Federal State Budgetary Educational Institution of Higher Education “Novosibirsk State Medical University”, Ministry of Health of the Russian Federation.

Rechkunovskaya ul. 15, Novosibirsk, 630055; Savinykh ul. 12/1, Tomsk, 634028; Krasny Prospekt 52, Novosibirsk, 630091

Tel.: (913) 824-60-72

Author ID 55220758100; Reseacher ID (WOS) C-8608-2012

alacher@list.ruhttps://orcid.org/0000-0003-0829-0340ЧерняковА. А.ChernyakovA. A.

Черняков Александр Алексеевич – врач-ординатор.

634028, Томск, ул. Савиных, 12 / 1

Тел.: (913) 108-23-45

Author ID 1172939

Alexander A. Chernyakov - Resident Physician, Cancer Research Institute – Subdivision of the Federal State Budgetary Scientific Institution “Tomsk National Research Medical Center of the Russian Academy of Sciences”.

Savinykh ul. 12/1, Tomsk, 634028

Tel.: (913) 108-23-45

Author ID 1172939

a.cherniackow@yandex.ruhttps://orcid.org/0000-0001-5926-2601ТрущукЮ. М.TrushjukJu. M.

Трущук Юлия Михайловна – врач отделения онкологии № 4.

634028, Томск, ул. Савиных, 12 / 1

Тел.: (953) 913-25-08

Author ID 667545

Julia M. Trushjuk - Doctor, Oncology Department No.4, Cancer Research Institute – Subdivision of the Federal State Budgetary Scientific Institution “Tomsk National Research Medical Center of the Russian Academy of Sciences”.

Savinykh ul. 12/1, Tomsk, 634028

Tel.: (953) 913-25-08

Author ID: 667545

julija-bilina@mail.ruhttps://orcid.org/0000-0001-6562-7574ДильО. С.DilO. S.

Диль Ольга Сергеевна – врач-онколог Института онкологии и нейрохирургии.

630055, Новосибирск, ул. Речкуновская, 15

Тел.: (913) 852-89-60

Author ID 1142135

Olga S. Dil - Oncologist, Institute of Oncology and Neurosurgery, Federal State Budgetary Institution “National Medical Research Center named after Academician E.N. Meshalkin”, Ministry of Health of the Russian Federation.

Rechkunovskaya ul. 15, Novosibirsk, 630055

Tel.: (913) 852-89-60

Author ID 1142135

lyabisheva.os@mail.ruЧернышоваА. Е.ChernyshovaA. E.

Чернышова Арина Евгеньевна – студентка.

199034, Санкт-Петербург, Университетская набережная, 7–9

Тел.: (983) 239-84-74

Arina E. Chernyshova - Student, Federal State Budgetary Educational Institution of Higher Education “St. Petersburg State University”, Government of the Russian Federation.

Universitetskaya Naberezhnaya 7/9, Saint-Petersburg, 199034

Tel.: (983) 239-84-74

utu98_29@icloud.comФедеральное государственное бюджетное учреждение «Национальный медицинский исследовательский центр имени академика Е.Н. Мешалкина» Министерства здравоохранения Российской Федерации; Научно-исследовательский институт онкологии – филиал Федерального государственного бюджетного научного учреждения «Томский национальный исследовательский медицинский центр Российской академии наук»; Федеральное государственное бюджетное образовательное учреждение высшего образования «Новосибирский государственный медицинский университет» Министерства здравоохранения Российской ФедерацииРоссияFederal State Budgetary Institution “National Medical Research Center named after Academician E.N. Meshalkin”, Ministry of Health of the Russian Federation; Cancer Research Institute Cancer Research Institute is a Subdivision of the Federal State Budgetary Scientific Institution “Tomsk National Research Medical Center of the Russian Academy of Sciences”; Federal State Budgetary Educational Institution of Higher Education “Novosibirsk State Medical University”, Ministry of Healthcare of Russian FederationRussian FederationНаучно-исследовательский институт онкологии – филиал Федерального государственного бюджетного научного учреждения «Томский национальный исследовательский медицинский центр Российской академии наук»РоссияCancer Research Institute Cancer Research Institute is a Subdivision of the Federal State Budgetary Scientific Institution “Tomsk National Research Medical Center of the Russian Academy of Sciences”Russian FederationФедеральное государственное бюджетное учреждение «Национальный медицинский исследовательский центр имени академика Е.Н. Мешалкина» Министерства здравоохранения Российской ФедерацииРоссияFederal State Budgetary Institution “National Medical Research Center named after Academician E.N. Meshalkin”, Ministry of Health of the Russian FederationRussian FederationФедеральное государственное бюджетное образовательное учреждение высшего образования «Санкт-Петербургский государственный университет» Правительства Российской ФедерацииРоссияFederal State Budgetary Educational Institution of Higher Education “St. Petersburg State University”, Government of the Russian FederationRussian Federation202418082024344544551Copyright © Чернышова А.Л., Черняков А.А., Трущук Ю.М., Диль О.С., Чернышова А.Е., 20242024Чернышова А.Л., Черняков А.А., Трущук Ю.М., Диль О.С., Чернышова А.Е.Chernyshova A.L., Chernyakov A.A., Trushjuk J.M., Dil O.S., Chernyshova A.E.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://journal.pulmonology.ru/pulm/article/view/4389

По данным мировой статистики, рак легкого (РЛ) занимает 2-е ранговое место в структуре онкологической заболеваемости среди женщин. Ведение РЛ, ассоциированного с беременностью, представляет собой клиническую дилемму, поскольку необходимо учитывать возможные риски в отношении не только матери, но и плода. Целью работы явилось изучение существующих литературных данных о диагностике, тактике ведения и лечебных подходах при РЛ, ассоциированном с беременностью. По данным литературных источников и представленных клинических наблюдений показаны неутешительные результаты: практически не наблюдалось ответа на химиотерапию (ХТ) у пациенток, получавших ХТ комбинациями платины с винорелбином, паклитакселом и этопозидом во время беременности и после родов, при этом сделан предварительный вывод о том, что изменение фармакокинетики химиопрепаратов может поставить под угрозу лечение онкологического заболевания во время беременности. Применение хирургического и лучевого методов лечения зависит от конкретной клинической ситуации, стадии и гистотипа опухоли, а также срока беременности. Заключение. Таким образом, как диагностические, так и лечебные мероприятия в отношении беременных женщин с РЛ должны быть персонализированными и выполняться специальной мультидисциплинарной командой, включающей в себя химиотерапевта, радиотерапевта, онколога-хирурга и акушера-гинеколога.

According to world statistics, lung cancer (LC) ranks 2nd in the cancer incidence among women. Management of pregnancy-associated LC presents a clinical dilemma, as it is necessary to consider possible risks not only for the mother, but also for the fetus. The aim of the work was to study the existing literature data on diagnosis, management tactics and treatment approaches for pregnancy-associated cancer. The literature sources and presented clinical observations show disappointing findings: there was practically no response to chemotherapy (CT) in patients who received chemotherapy with platinum in combination with vinorelbine, paclitaxel, and etoposide during pregnancy and after childbirth, and a preliminary conclusion was made that change in the pharmacokinetics of chemotherapy drug may jeopardize the treatment of cancer during pregnancy. The use of surgical and radiation treatment methods depends on the individual clinical situation, stage and histotype of the tumor, as well as the gestational age. Conclusion. Thus, both diagnostic and therapeutic measures for pregnant women with LC should be personalized and performed by a special multidisciplinary team that includes a chemotherapist, radiotherapist, surgical oncologist, and obstetrician-gynecologist.

беременностьрак легкоголечениедиагностикапрогнозpregnancylung cancertreatmentdiagnosisprognosisReferencesVoulgaris E., Pentheroudakis G., Pavlidis N. Cancer and pregnancy: a comprehensive review. Surg. Oncol. 2011; 20 (4): e175–185. DOI: 10.1016/j.suronc.2011.06.002.Voulgaris E., Pentheroudakis G., Pavlidis N. Cancer and pregnancy: a comprehensive review. Surg. Oncol. 2011; 20 (4): e175–185. DOI: 10.1016/j.suronc.2011.06.002.Pentheroudakis G., Pavlidis N. Gastrointestinal, urologic and lung malignancies during pregnancy. Recent Results Cancer Res. 2008; 178: 137–164. DOI: 10.1007/978-3-540-71274-9_13.Pentheroudakis G., Pavlidis N. Gastrointestinal, urologic and lung malignancies during pregnancy. Recent Results Cancer Res. 2008; 178: 137–164. DOI: 10.1007/978-3-540-71274-9_13.Boussios S., Han S.N., Fruscio R. et al. Lung cancer in pregnancy: report of nine cases from an international collaborative study. Lung Cancer. 2013; 82 (3): 499–505. DOI: 10.1016/j.lungcan.2013.09.002.Boussios S., Han S.N., Fruscio R. et al. Lung cancer in pregnancy: report of nine cases from an international collaborative study. Lung Cancer. 2013; 82 (3): 499–505. DOI: 10.1016/j.lungcan.2013.09.002.Jemal A., Siegel R., Ward E. et al. Cancer statistics, 2006. CA Cancer J. Clin. 2006; 56 (2): 106–130. DOI: 10.3322/canjclin.56.2.106.Jemal A., Siegel R., Ward E. et al. Cancer statistics, 2006. CA Cancer J. Clin. 2006; 56 (2): 106–130. DOI: 10.3322/canjclin.56.2.106.Barr J.S. Placental metastases from a bronchial carcinoma. J. Obstet. Gynaecol. Br. Emp. 1953; 60 (6): 895–897. DOI: 10.1111/j.1471-0528.1953.tb07292.x.Barr J.S. Placental metastases from a bronchial carcinoma. J. Obstet. Gynaecol. Br. Emp. 1953; 60 (6): 895–897. DOI: 10.1111/j.1471-0528.1953.tb07292.x.Azim H.A. Jr., Peccatori F.A., Pavlidis N. Lung cancer in the pregnant woman: to treat or not to treat, that is the question. Lung Cancer. 2010; 67 (3): 251–256. DOI: 10.1016/j.lungcan.2009.10.006.Azim H.A. Jr., Peccatori F.A., Pavlidis N. Lung cancer in the pregnant woman: to treat or not to treat, that is the question. Lung Cancer. 2010; 67 (3): 251–256. DOI: 10.1016/j.lungcan.2009.10.006.Hayama M., Chida M., Tamura M. et al. Unexpected rapid growth of estrogen receptor positive lung cancer during pregnancy. Ann. Thorac. Cardiovasc. Surg. 2014; 20 (4): 325–328. DOI: 10.5761/atcs.cr.12.01934.Hayama M., Chida M., Tamura M. et al. Unexpected rapid growth of estrogen receptor positive lung cancer during pregnancy. Ann. Thorac. Cardiovasc. Surg. 2014; 20 (4): 325–328. DOI: 10.5761/atcs.cr.12.01934.Sarıman N., Levent E., Yener N.A. et al. Lung cancer and pregnancy. Lung Cancer. 2013; 79 (3): 321–323. DOI: 10.1016/j.lungcan.2012.11.014.Sarıman N., Levent E., Yener N.A. et al. Lung cancer and pregnancy. Lung Cancer. 2013; 79 (3): 321–323. DOI: 10.1016/j.lungcan.2012.11.014.Ceauşu M., Hostiuc S., Sajin M. et al. Gestational lung adenocarcinoma: case report. Int. J. Surg. Pathol. 2014; 22 (7): 663–666. DOI: 10.1177/1066896914531816.Ceauşu M., Hostiuc S., Sajin M. et al. Gestational lung adenocarcinoma: case report. Int. J. Surg. Pathol. 2014; 22 (7): 663–666. DOI: 10.1177/1066896914531816.Kim J.W., Kim J.S., Cho J.Y., Lee D.H. Successful video-assisted thoracoscopic lobectomy in a pregnant woman with lung cancer. Lung Cancer. 2014; 85 (2): 331–334. DOI: 10.1016/j.lungcan.2014.05.022.Kim J.W., Kim J.S., Cho J.Y., Lee D.H. Successful video-assisted thoracoscopic lobectomy in a pregnant woman with lung cancer. Lung Cancer. 2014; 85 (2): 331–334. DOI: 10.1016/j.lungcan.2014.05.022.Neves I., Mota P.C., Hespanhol V.P. Lung cancer during pregnancy: an unusual case. Rev. Port. Pneumol. 2014; 20 (1): 46–49. DOI: 10.1016/j.rppneu.2013.06.005.Neves I., Mota P.C., Hespanhol V.P. Lung cancer during pregnancy: an unusual case. Rev. Port. Pneumol. 2014; 20 (1): 46–49. DOI: 10.1016/j.rppneu.2013.06.005.Gil S., Goetgheluck J., Paci A. et al. Efficacy and safety of gefitinib during pregnancy: case report and literature review. Lung Cancer. 2014; 85 (3): 481–484. DOI: 10.1016/j.lungcan.2014.06.003.Gil S., Goetgheluck J., Paci A. et al. Efficacy and safety of gefitinib during pregnancy: case report and literature review. Lung Cancer. 2014; 85 (3): 481–484. DOI: 10.1016/j.lungcan.2014.06.003.Wang A., Kubo J., Luo J. et al. Active and passive smoking in relation to lung cancer incidence in the Women's Health Initiative Observational study prospective cohort. Ann. Oncol. 2015; 26 (1): 221–230. DOI: 10.1093/annonc/mdu470.Wang A., Kubo J., Luo J. et al. Active and passive smoking in relation to lung cancer incidence in the Women's Health Initiative Observational study prospective cohort. Ann. Oncol. 2015; 26 (1): 221–230. DOI: 10.1093/annonc/mdu470.Lortet-Tieulent J., Soerjomataram I., Ferlay J. et al. International trends in lung cancer incidence by histological subtype: adenocarcinoma stabilizing in men but still increasing in women. Lung Cancer. 2014; 84 (1): 13–22. DOI: 10.1016/j.lungcan.2014.01.009.Lortet-Tieulent J., Soerjomataram I., Ferlay J. et al. International trends in lung cancer incidence by histological subtype: adenocarcinoma stabilizing in men but still increasing in women. Lung Cancer. 2014; 84 (1): 13–22. DOI: 10.1016/j.lungcan.2014.01.009.Azim H.A. Jr., Peccatori F.A., Pavlidis N. Treatment of the pregnant mother with cancer: a systematic review on the use of cytotoxic, endocrine, targeted agents and immunotherapy during pregnancy. Part I: Solid tumors. Cancer Treat. Rev. 2010; 36 (2): 101–109. DOI: 10.1016/j.ctrv.2009.11.007.Azim H.A. Jr., Peccatori F.A., Pavlidis N. Treatment of the pregnant mother with cancer: a systematic review on the use of cytotoxic, endocrine, targeted agents and immunotherapy during pregnancy. Part I: Solid tumors. Cancer Treat. Rev. 2010; 36 (2): 101–109. DOI: 10.1016/j.ctrv.2009.11.007.Pavlidis N., Peccatori F.A., Lofts F., Greco A.F. Cancer of unknown primary during pregnancy: an exceptionally rare coexistence. Anticancer Res. 2015; 35 (1): 575–579. Available at: https://ar.iiarjournals.org/content/35/1/575Pavlidis N., Peccatori F.A., Lofts F., Greco A.F. Cancer of unknown primary during pregnancy: an exceptionally rare coexistence. Anticancer Res. 2015; 35 (1): 575–579. Available at: https://ar.iiarjournals.org/content/35/1/575Pentheroudakis G., Orecchia R., Hoekstra H.J. et al. Cancer, fertility and pregnancy: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 2010; 21 (Suppl. 5): v266–273. DOI: 10.1093/annonc/mdq198.Pentheroudakis G., Orecchia R., Hoekstra H.J. et al. Cancer, fertility and pregnancy: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 2010; 21 (Suppl. 5): v266–273. DOI: 10.1093/annonc/mdq198.Olsen J., Pedersen L.H. Reproductive health indicators and fetal medicine – many things will change. Scand. J. Work Environ. Health. 2016; 42 (6): 561–562. DOI: 10.5271/sjweh.3596.Olsen J., Pedersen L.H. Reproductive health indicators and fetal medicine – many things will change. Scand. J. Work Environ. Health. 2016; 42 (6): 561–562. DOI: 10.5271/sjweh.3596.Soberanis Pina P., Lara-Mej´ıa L., Matias-Cruz V. et al. Case report: Osimertinib administration during pregnancy in a woman with advanced EGFR-mutant non-small cell lung cancer. Front. Oncol. 2023; 13:1108124. DOI: 10.3389/fonc.2023.1108124.Soberanis Pina P., Lara-Mej´ıa L., Matias-Cruz V. et al. Case report: Osimertinib administration during pregnancy in a woman with advanced EGFR-mutant non-small cell lung cancer. Front. Oncol. 2023; 13:1108124. DOI: 10.3389/fonc.2023.1108124.Sung H., Ferlay J., Siegel R.L. et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 2021; 71 (3): 209–249. DOI: 10.3322/caac.21660.Sung H., Ferlay J., Siegel R.L. et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 2021; 71 (3): 209–249. DOI: 10.3322/caac.21660.Arrieta O., Zatarain-Barrón Z.L., Aldaco F. et al. Lung cancer in Mexico. J. Thorac. Oncol. 2019; 14 (10):1695–700. DOI: 10.1016/j.jtho.2019.05.018.Arrieta O., Zatarain-Barrón Z.L., Aldaco F. et al. Lung cancer in Mexico. J. Thorac. Oncol. 2019; 14 (10):1695–700. DOI: 10.1016/j.jtho.2019.05.018.Bellido C., Barbero P., Forcén L. et al. Lung adenocarcinoma during pregnancy: clinical case and literature review. J. Maternal. Fetal Neonatal Med. 2019; 32 (19): 3300–3302. DOI: 10.1080/14767058.2018.1461830.Bellido C., Barbero P., Forcén L. et al. Lung adenocarcinoma during pregnancy: clinical case and literature review. J. Maternal. Fetal Neonatal Med. 2019; 32 (19): 3300–3302. DOI: 10.1080/14767058.2018.1461830.Passaro A., Leighl N., Blackhall F et al. ESMO expert consensus statements on the management of EGFR mutant non-small-cell lung cancer. Ann. Oncol. 2022. 33 (5): 466–487. DOI: 10.1016/j.annonc.2022.02.003.Passaro A., Leighl N., Blackhall F et al. ESMO expert consensus statements on the management of EGFR mutant non-small-cell lung cancer. Ann. Oncol. 2022. 33 (5): 466–487. DOI: 10.1016/j.annonc.2022.02.003.Rosell R., Cardona A.F., Arrieta O. et al. Coregulation of pathways in lung cancer patients with EGFR mutation: therapeutic opportunities. Br. J. Cancer. 2021; 125: 1602–1611. DOI: 10.1038/s41416-021-01519-2.Rosell R., Cardona A.F., Arrieta O. et al. Coregulation of pathways in lung cancer patients with EGFR mutation: therapeutic opportunities. Br. J. Cancer. 2021; 125: 1602–1611. DOI: 10.1038/s41416-021-01519-2.Corrales-Rodrıguez L., Arrieta O., Mas L. et al. An international epidemiological analysis of young patients with nonsmall cell lung cancer (AduJov-CLICaP). Lung Cancer. 2017; 113: 30–36. DOI: 10.1016/j.lungcan.2017.08.022.Corrales-Rodrıguez L., Arrieta O., Mas L. et al. An international epidemiological analysis of young patients with nonsmall cell lung cancer (AduJov-CLICaP). Lung Cancer. 2017; 113: 30–36. DOI: 10.1016/j.lungcan.2017.08.022.Dagogo-Jack I., Gainor J.F., Porter R.L. et al. Clinicopathologic features of NSCLC diagnosed during pregnancy or the peripartum period in the era of molecular genotyping. J. Thorac. Oncol. 2016; 11 (9): 1522–1528. DOI: 10.1016/j.jtho.2016.05.031.Dagogo-Jack I., Gainor J.F., Porter R.L. et al. Clinicopathologic features of NSCLC diagnosed during pregnancy or the peripartum period in the era of molecular genotyping. J. Thorac. Oncol. 2016; 11 (9): 1522–1528. DOI: 10.1016/j.jtho.2016.05.031.Jin J., Wu X., Yin J. et al. Identification of genetic mutations in cancer: Challenge and opportunity in the new era of targeted therapy. Front. Oncol. 2019; 9: 263. DOI: 10.3389/FONC.2019.00263.Jin J., Wu X., Yin J. et al. Identification of genetic mutations in cancer: Challenge and opportunity in the new era of targeted therapy. Front. Oncol. 2019; 9: 263. DOI: 10.3389/FONC.2019.00263.Kooijman J.J., van Riel W.E., Dylus J. et al. Comparative kinase and cancer cell panel profiling of kinase inhibitors approved for clinical use from 2018 to 2020. Front. Oncol. 2022; 12: 953013. DOI: 10.3389/FONC.2022.953013.Kooijman J.J., van Riel W.E., Dylus J. et al. Comparative kinase and cancer cell panel profiling of kinase inhibitors approved for clinical use from 2018 to 2020. Front. Oncol. 2022; 12: 953013. DOI: 10.3389/FONC.2022.953013.Qi Y., Xia X., Shao L. et al. An updated network metaanalysis of EGFR-TKIs and combination therapy in the first-line treatment of advanced EGFR mutation positive non-small cell lung cancer. Front. Oncol. 2022; 12: 616546. DOI: 10.3389/FONC.2022.616546.Qi Y., Xia X., Shao L. et al. An updated network metaanalysis of EGFR-TKIs and combination therapy in the first-line treatment of advanced EGFR mutation positive non-small cell lung cancer. Front. Oncol. 2022; 12: 616546. DOI: 10.3389/FONC.2022.616546.Rayego-Mateos S., Rodrigues-Diez R., Morgado-Pascual J.L. et al. Role of epidermal growth factor receptor (EGFR) and its ligands in kidney inflammation and damage. Mediators Inflamm. 2018; 2018: 8739473. DOI: 10.1155/2018/8739473.Rayego-Mateos S., Rodrigues-Diez R., Morgado-Pascual J.L. et al. Role of epidermal growth factor receptor (EGFR) and its ligands in kidney inflammation and damage. Mediators Inflamm. 2018; 2018: 8739473. DOI: 10.1155/2018/8739473.Robinson A.A., Watson W.J., Leslie K.K. Targeted treatment using monoclonal antibodies and tyrosine-kinase inhibitors in pregnancy. Lancet Oncol. 2007; 8 (8): 738–743. DOI: 10.1016/S1470-2045(07)70242-5.Robinson A.A., Watson W.J., Leslie K.K. Targeted treatment using monoclonal antibodies and tyrosine-kinase inhibitors in pregnancy. Lancet Oncol. 2007; 8 (8): 738–743. DOI: 10.1016/S1470-2045(07)70242-5.Boudy A.S., Grausz N., Selleret L. et al. Use of tyrosine kinase inhibitors during pregnancy for oncogenic-driven advanced non-small cell lung carcinoma. Lung Cancer. 2021; 161: 68–75. DOI: 10.1016/j.lungcan.2021.09.001.Boudy A.S., Grausz N., Selleret L. et al. Use of tyrosine kinase inhibitors during pregnancy for oncogenic-driven advanced non-small cell lung carcinoma. Lung Cancer. 2021; 161: 68–75. DOI: 10.1016/j.lungcan.2021.09.001.Kim Y., Lee S.H., Ahn J.S. et al. Efficacy and safety of afatinib for EGFR-mutant non-small cell lung cancer, compared with gefitinib or erlotinib. Cancer Res. Treat. 2019; 51 (2): 502–509. DOI: 10.4143/CRT.2018.117.Kim Y., Lee S.H., Ahn J.S. et al. Efficacy and safety of afatinib for EGFR-mutant non-small cell lung cancer, compared with gefitinib or erlotinib. Cancer Res. Treat. 2019; 51 (2): 502–509. DOI: 10.4143/CRT.2018.117.Orefice R. Immunology and the immunological response in pregnancy. Best Pract. Res. Clin. Obstetю Gynaecol. 2021. 76: 3–12. DOI: 10.1016/J.BPOBGYN.2020.07.013.Orefice R. Immunology and the immunological response in pregnancy. Best Pract. Res. Clin. Obstetю Gynaecol. 2021. 76: 3–12. DOI: 10.1016/J.BPOBGYN.2020.07.013.Kareva I. Immune suppression in pregnancy and cancer: parallels and insights. Transl. Oncol. 2020; 13 (7): 100759. DOI: 10.1016/J.TRANON.2020.100759.Kareva I. Immune suppression in pregnancy and cancer: parallels and insights. Transl. Oncol. 2020; 13 (7): 100759. DOI: 10.1016/J.TRANON.2020.100759.Rodriguez-Lara V., Hernandez-Martinez J.M., Arrieta O. Influence of estrogen in non-small cell lung cancer and its clinical implications. J. Thorac Dis. 2018; 10 (1): 482–497. DOI: 10.21037/JTD.2017.12.61.Rodriguez-Lara V., Hernandez-Martinez J.M., Arrieta O. Influence of estrogen in non-small cell lung cancer and its clinical implications. J. Thorac Dis. 2018; 10 (1): 482–497. DOI: 10.21037/JTD.2017.12.61.Кузнецов П.А., Оленев А.С., Джохадзе Л.С., Селиверстова О.М. Влияние ионизирующего излучения на плод. Российский вестник акушера-гинеколога. 2018; 18 (5): 32–35. DOI: 10.17116/rosakush20181805132.Kuznetsov PA, Olenev AS, Dzhokhadze LS, Seliverstova OM. [Impact of ionizing radiation on the fetus]. Rossiyskiy vestnik akushera-ginekologa. 2018; 18 (5): 32–35. DOI: 10.17116/rosakush20181805132 (in Russian).Rosell R., Cardona A.F., Arrieta O. et al. Coregulation of pathways in lung cancer patients with EGFR mutation: therapeutic opportunities. Br. J. Cancer. 2021; 125 (12): 1602–1611. DOI: 10.1038/s41416-021-01519-2.Rosell R., Cardona A.F., Arrieta O. et al. Coregulation of pathways in lung cancer patients with EGFR mutation: therapeutic opportunities. Br. J. Cancer. 2021; 125 (12): 1602–1611. DOI: 10.1038/s41416-021-01519-2.

The authors declare that there are no conflicts of interest present.